6. Pfizer Sales were up just 2%, but cost-cutting, as well as the sale of the company's consumer-products division to Johnson & Johnson, helped profits jump 139% to $19.3 billion. Still, like many of its Big Pharma counterparts, Pfizer is scrambling to make up for the blockbuster drugs it has going off-patent, like allergy remedy Zyrtec. | |